SLC1A5 and acute myeloid leukemia: Key targets in the Gln metabolic pathway, such as proto-oncogenes, glutamic-pyruvic transaminase 2, and solute carrier family 1 member 5, are regulated by insulin-like growth factor 2 mRNA-binding protein 2 in an m6A-dependent manner to promote AML development and stem cell self-renewal [23].